GlassScriptPhysician profile
Colleen Heniff
NPI 1972509594
$7,523.26
in general payments reported to CMS, 2019-2025
25 companies · $17.86 in 2025
The $17.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $1,025 · 2021: $1,510 · 2022: $1,439 · 2023: $1,468 · 2024: $853 · 2025: $17.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.33 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.92 | 2019-2024 | |
| Lilly USA, LLC | $1,196.48 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $892.00 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $754.53 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $717.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.81 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $359.11 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $255.77 | 2019-2024 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $193.83 | 2021-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $189.93 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $186.00 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $157.57 | 2021-2023 | |
| Exact Sciences Corporation | $112.67 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $110.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $96.12 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88.59 | 2021-2023 | Veozah |
| Abbott Laboratories | $87.79 | 2021-2024 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $56.10 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $55.34 | 2021 | |
| Amarin Pharma, INC. | $41.92 | 2019 | |
| Medtronic, INC. | $39.38 | 2022 | |
| Mylan Specialty L.P. | $29.24 | 2019 | |
| Edwards Lifesciences Corporation | $17.86 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ironwood Pharmaceuticals, INC | $17.50 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.14 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Heniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.